Abstract
This study using data from the Veterans Affairs (VA) administrative and clinical dataset examined determinants of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) use among patients with concomitant atherosclerotic cardiovascular disease (ASCVD) and diabetes mellitus. The aim of the present analysis was to identify barriers and facilitators associated with SGLT-2i in a real-world contemporary patient population in order to improve utilization of these guideline-directed agents.
Original language | English |
---|---|
Pages (from-to) | 160-162 |
Number of pages | 3 |
Journal | American Heart Journal |
Volume | 248 |
DOIs | |
Publication status | Published - Jun 2022 |
Externally published | Yes |